China Aoxing Pharmaceutical Company (AXN) 0.55 $AXN
Aoxing Pharmaceutical Company, Inc. Announces Private Sale of Common Stock
ACCESSWIRE - Mon Feb 09, 7:31AM CST
JERSEY CITY, NJ / ACCESSWIRE / February 9, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced that it has completed the sale of 1,704,915 shares of its common stock to six investors, each of whom is either an employee or a consultant to Aoxing Pharma. The largest purchase was by Wilfred Chow, who became the Chief Financial Officer of Aoxing Pharma on January 1, 2015. Mr. Chow purchased 812,500 shares. The purchase price for the shares was $.33 per share, which was the market price when the purchase agreements were signed. The total added to Aoxing Pharma's capital was $545,573.
AXN: 0.55 (+0.04)
NYSE Market Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time for Compliance
ACCESSWIRE - Fri Jan 30, 12:56PM CST
JERSEY CITY, NJ / ACCESSWIRE / January 30, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide:
AXN: 0.55 (+0.04)
OTC Daily Alert Stock Watch - Aoxing Pharmaceutical Company, Inc. (NYSE: AXN)
WorldStockWire - Mon Dec 29, 5:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Appointment of CFO and Independent Director
ACCESSWIRE - Mon Dec 29, 7:45AM CST
Untitled Document
AXN: 0.55 (+0.04)
NYSE MKT Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time For Compliance
ACCESSWIRE - Fri Dec 19, 2:47PM CST
JERSEY CITY, NY / ACCESSWIRE / December 19, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide:
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for First Quarter of 2015 Fiscal Year
ACCESSWIRE - Fri Nov 14, 3:30PM CST
JERSEY CITY, NJ / ACCESSWIRE / November 14, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three month period ended September 30, 2014. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on November 14, 2014.
AXN: 0.55 (+0.04)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 14.92 (+0.93), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), AXN: 0.55 (+0.04), SRNE: 11.41 (+0.56), NKTR: 13.54 (-0.14), EGLT: 10.60 (+0.58), AZN: 69.96 (+0.20), VBAY: ()
NYSE MKT Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time for Compliance and That a Reverse Stock Split Would be Appropriate
ACCESSWIRE - Fri Oct 24, 6:31PM CDT
JERSEY CITY, NJ / ACCESSWIRE / Oct 24, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide:
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Receives Audit Opinion With Going Concern Explanation
Marketwire - Fri Oct 03, 7:11PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management and addiction treatment pharmaceuticals, today announced that its audited consolidated financial statements for the fiscal year ended June 30, 2014, included in the Company's Annual Report on Form 10-K, which was filed on September 29, 2014 with the Securities and Exchange Commission, contain an audit opinion from its independent registered public accounting firm that includes a going concern qualification.
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company posts lower loss from operations of USD3.335m in fiscal 2014
M2 - Tue Sep 30, 6:48AM CDT
Pharmaceutical company Aoxing Pharmaceutical Company (NYSE MKT:AXN) on Monday reported a loss from operations of USD3.335m for the year ended 30 June 2014.
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for 2014 Fiscal Year
Marketwire - Mon Sep 29, 12:11PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the year ended June 30, 2014. Complete financial results can be found in the Annual Report on Form 10-K filed by Aoxing Pharma on September 29, 2014.
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension From NYSE MKT LLC
Marketwire - Wed Aug 06, 6:15AM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma" , a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide:
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Private Sale of Common Stock
ACCESSWIRE - Mon Feb 09, 7:31AM CST
JERSEY CITY, NJ / ACCESSWIRE / February 9, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced that it has completed the sale of 1,704,915 shares of its common stock to six investors, each of whom is either an employee or a consultant to Aoxing Pharma. The largest purchase was by Wilfred Chow, who became the Chief Financial Officer of Aoxing Pharma on January 1, 2015. Mr. Chow purchased 812,500 shares. The purchase price for the shares was $.33 per share, which was the market price when the purchase agreements were signed. The total added to Aoxing Pharma's capital was $545,573. AXN: 0.55 (+0.04)
NYSE Market Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time for Compliance
ACCESSWIRE - Fri Jan 30, 12:56PM CST
JERSEY CITY, NJ / ACCESSWIRE / January 30, 2015 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide: AXN: 0.55 (+0.04)
OTC Daily Alert Stock Watch - Aoxing Pharmaceutical Company, Inc. (NYSE: AXN)
WorldStockWire - Mon Dec 29, 5:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Appointment of CFO and Independent Director
ACCESSWIRE - Mon Dec 29, 7:45AM CST
Untitled Document
AXN: 0.55 (+0.04)
NYSE MKT Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time For Compliance
ACCESSWIRE - Fri Dec 19, 2:47PM CST
JERSEY CITY, NY / ACCESSWIRE / December 19, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide: AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for First Quarter of 2015 Fiscal Year
ACCESSWIRE - Fri Nov 14, 3:30PM CST
JERSEY CITY, NJ / ACCESSWIRE / November 14, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three month period ended September 30, 2014. Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on November 14, 2014. AXN: 0.55 (+0.04)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 14.92 (+0.93), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), AXN: 0.55 (+0.04), SRNE: 11.41 (+0.56), NKTR: 13.54 (-0.14), EGLT: 10.60 (+0.58), AZN: 69.96 (+0.20), VBAY: ()
NYSE MKT Notifies Aoxing Pharmaceutical Company, Inc. of Extension of Time for Compliance and That a Reverse Stock Split Would be Appropriate
ACCESSWIRE - Fri Oct 24, 6:31PM CDT
JERSEY CITY, NJ / ACCESSWIRE / Oct 24, 2014 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide: AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Receives Audit Opinion With Going Concern Explanation
Marketwire - Fri Oct 03, 7:11PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management and addiction treatment pharmaceuticals, today announced that its audited consolidated financial statements for the fiscal year ended June 30, 2014, included in the Company's Annual Report on Form 10-K, which was filed on September 29, 2014 with the Securities and Exchange Commission, contain an audit opinion from its independent registered public accounting firm that includes a going concern qualification.
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company posts lower loss from operations of USD3.335m in fiscal 2014
M2 - Tue Sep 30, 6:48AM CDT
Pharmaceutical company Aoxing Pharmaceutical Company (NYSE MKT:AXN) on Monday reported a loss from operations of USD3.335m for the year ended 30 June 2014.
AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Announces Financial Results for 2014 Fiscal Year
Marketwire - Mon Sep 29, 12:11PM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the year ended June 30, 2014. Complete financial results can be found in the Annual Report on Form 10-K filed by Aoxing Pharma on September 29, 2014. AXN: 0.55 (+0.04)
Aoxing Pharmaceutical Company, Inc. Receives Notice of Extension From NYSE MKT LLC
Marketwire - Wed Aug 06, 6:15AM CDT
Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"
, a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, previously announced that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma's Annual Report on Form 10-K for the year ended June 30, 2013 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2013 and December 31, 2013, Aoxing Pharma is not in compliance with the following sections of the NYSE MKT Company Guide: AXN: 0.55 (+0.04)
